Avalyn Pharma Inc. Common Stock (AVLN) Stock
Fundamentals
Latest news
About Avalyn Pharma Inc. Common Stock
Avalyn Pharma Inc. is a clinical-stage biopharmaceutical firm pioneering inhaled therapies to transform the treatment paradigm for serious, rare respiratory diseases with significant unmet needs. Its approach is designed to address the limitations of current oral therapies by delivering optimized inhaled formulations of approved oral medicines directly to the lungs, enhancing efficacy while minimizing systemic exposure that contributes to side effects and treatment discontinuation. Its current pipeline is focused on treating pulmonary fibrosis, a life-threatening disease with a median survival of three to five years, representing a significantly shorter prognosis than that observed for many forms of cancer.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Lyn Baranowski | CEO, President & Director | 1976 |
| Mr. Douglas R. Carlson | CFO & Chief Business Officer | 1979 |
| Dr. Melissa Rhodes DABT, Ph.D. | Chief Operating Officer | 1978 |
| Dr. Howard M. Lazarus M.D. | Chief Medical Officer | 1966 |
| Ms. Cassie Saitow | Senior Director of IR & Corporate Communications | — |
| Mr. Adam H, Golden J.D. | General Counsel & Head of Business Development | 1964 |
| Dr. Craig Conoscenti M.D. | Senior Vice President of Clinical Development | — |
| Mr. James Bishop | Senior Vice President of Business Operations | — |
| Dr. Stephen Pham Ph.D. | Senior Vice President of Product Development | — |
| Ms. Michelle Patterson M.B.A., P.M.P. | Senior Vice President of Corporate Planning & Portfolio Strategy | — |



